CompletedNCT00510211
Olanzapine use in outpatients with schizophrenia or bipolarity
About this title
Read the official source — NCT00510211Observational studyAges 18+Multiple countries
Understand this study
What did researchers investigate?
This study evaluated the effectiveness of olanzapine for people with bipolarity.
Who was this study for?
Listed age limits: from 18 years.
- Listed locations
- Paris and 2 more locationsSee all locations and recruitment
Study information
Study start dateApril 2007
- Recruitment status
- Completed
- Enrollment listed in the registry
- 1,131
- Sponsor
- Eli Lilly and Company
- Sponsor type
- Other organization
- Study type
- Observational
- Intervention type
- Medication / drug
- Study phase
- Not clearly listed
- Locations
- France, Germany, Greece
- Age range
- Over 18 Years
- Official registry ID
- NCT00510211
- Official title
Show the full official title
An Observational Study of Olanzapine Coated and Orodispersible Tablets Effectiveness in Schizophrenic and Bipolar Outpatients.
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedParis, France · Bad Homburg, Germany · Thessaloniki, Greece
Questions about this study
What did researchers investigate?
This study evaluated the effectiveness of olanzapine for people with bipolarity.
Who is behind this study?
The study sponsor is Eli Lilly and Company.
Did this study involve medication?
Yes. The study involved medication, including olanzapine.
Who was this study for?
Listed age limits: from 18 years.
